Cargando…
Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs
Pyoderma gangrenosum (PG) is a relatively rare neutrophilic dermatosis presenting as a rapidly progressive and painful skin ulcer characterized by undermined borders and peripheral erythema. Immunosuppressive therapy is the first-line treatment for PG; however, large ulcers often take months or year...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739536/ https://www.ncbi.nlm.nih.gov/pubmed/36498498 http://dx.doi.org/10.3390/jcm11236924 |
_version_ | 1784847831105798144 |
---|---|
author | Nishimura, Mai Mizutani, Kento Yokota, Naho Goto, Hiroyuki Akeda, Tomoko Kitagawa, Hiroshi Habe, Koji Hayashi, Akinobu Yamanaka, Keiichi |
author_facet | Nishimura, Mai Mizutani, Kento Yokota, Naho Goto, Hiroyuki Akeda, Tomoko Kitagawa, Hiroshi Habe, Koji Hayashi, Akinobu Yamanaka, Keiichi |
author_sort | Nishimura, Mai |
collection | PubMed |
description | Pyoderma gangrenosum (PG) is a relatively rare neutrophilic dermatosis presenting as a rapidly progressive and painful skin ulcer characterized by undermined borders and peripheral erythema. Immunosuppressive therapy is the first-line treatment for PG; however, large ulcers often take months or years to heal. Surgical treatments, such as negative pressure wound therapy (NPWT) and skin grafting, are still controversial due to the risk of inducing the pathergy phenomenon and eliciting PG development by traumatic factors. Herein, we report on four cases of PG treated with skin grafting, with or without NPWT, under the control of immunosuppressive drugs at our institution. All cases adapted well, but one case showed recurrence at the periphery of the grafted area five months postoperatively. The current patients were treated with the following doses of oral prednisolone (PSL): PSL 10 mg daily, PSL 5 mg daily + adalimumab 40 mg/week, PSL 12 mg + 6 mg of tacrolimus daily, and PSL 20 mg daily during skin grafting. No severe complications, including infections, were observed. Surgical treatments, such as skin grafting with or without NPWT, may accelerate wound healing, shorten the administration of analgesics and long-term immunosuppressive therapy, and reduce the risk of infection. |
format | Online Article Text |
id | pubmed-9739536 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97395362022-12-11 Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs Nishimura, Mai Mizutani, Kento Yokota, Naho Goto, Hiroyuki Akeda, Tomoko Kitagawa, Hiroshi Habe, Koji Hayashi, Akinobu Yamanaka, Keiichi J Clin Med Case Report Pyoderma gangrenosum (PG) is a relatively rare neutrophilic dermatosis presenting as a rapidly progressive and painful skin ulcer characterized by undermined borders and peripheral erythema. Immunosuppressive therapy is the first-line treatment for PG; however, large ulcers often take months or years to heal. Surgical treatments, such as negative pressure wound therapy (NPWT) and skin grafting, are still controversial due to the risk of inducing the pathergy phenomenon and eliciting PG development by traumatic factors. Herein, we report on four cases of PG treated with skin grafting, with or without NPWT, under the control of immunosuppressive drugs at our institution. All cases adapted well, but one case showed recurrence at the periphery of the grafted area five months postoperatively. The current patients were treated with the following doses of oral prednisolone (PSL): PSL 10 mg daily, PSL 5 mg daily + adalimumab 40 mg/week, PSL 12 mg + 6 mg of tacrolimus daily, and PSL 20 mg daily during skin grafting. No severe complications, including infections, were observed. Surgical treatments, such as skin grafting with or without NPWT, may accelerate wound healing, shorten the administration of analgesics and long-term immunosuppressive therapy, and reduce the risk of infection. MDPI 2022-11-24 /pmc/articles/PMC9739536/ /pubmed/36498498 http://dx.doi.org/10.3390/jcm11236924 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Nishimura, Mai Mizutani, Kento Yokota, Naho Goto, Hiroyuki Akeda, Tomoko Kitagawa, Hiroshi Habe, Koji Hayashi, Akinobu Yamanaka, Keiichi Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs |
title | Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs |
title_full | Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs |
title_fullStr | Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs |
title_full_unstemmed | Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs |
title_short | Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs |
title_sort | treatment strategy for pyoderma gangrenosum: skin grafting with immunosuppressive drugs |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739536/ https://www.ncbi.nlm.nih.gov/pubmed/36498498 http://dx.doi.org/10.3390/jcm11236924 |
work_keys_str_mv | AT nishimuramai treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs AT mizutanikento treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs AT yokotanaho treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs AT gotohiroyuki treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs AT akedatomoko treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs AT kitagawahiroshi treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs AT habekoji treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs AT hayashiakinobu treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs AT yamanakakeiichi treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs |